Methods	Six-week double-blind, randomised multicentre study.
Participants	Patients with ICD-10 depression, with a score between 16 and 24 points on HDRS. Age range: 18-73 years old. Exclusion criteria: participation in a clinical study less than 4 week, pregnancy and lactation, insufficient contraception, suicide risk, dementia, or othe severe intellectual impairment, chronic alcohol or drug abuse or dependence, severe cardiac, liver, kidney or respiratory insufficiency, neoplasia, Parkinson’s or Alzheimer’s disease, hypersensitivity to an ingredient of the Hypericum perforatum, febrile illness, anemia, thyroid or parathyroid disease, pituitary insufficiency
Interventions	Fluoxetine: 35 participants. Hypericum: 35. Fluoxetine dose: 40 mg/day. Hypericum dose: 300 mg/day.
Outcomes	Hamilton Rating Scale for Depression (HDRS-17), von Zerssen Depression Scale, Clinical Global Impression Scale
Notes	Funding: by industry
Risk of bias
Item	Authors’ judgement	Description
Allocation concealment?	Unclear	B - Unclear